| The symptoms
are sadly familiar: memory loss, vagueness, losing the point of a conversation,
repeating oneself. The decline is steady and downhill. The patient requires
increasing levels of care. Alzheimer's disease (AD) is the most common form
of late-life dementia, with approximately 4 million stricken in the U.S.
alone. Annual cost estimates, including the costs of medical, long-term
and home care, as well as caregiver productivity losses, approach $90 billion
yearly. As the babyboomers reach the age of 60 and older, the number of
Americans who will succumb to this disease may reach 14 million! The impact
on people's lives and the economy is staggering. New drugs are now available for patients with AD in its early stages. Donepezil (also known as Aricept) can temporarily stabilize the decline and improve memory function of patients with mild to moderate Alzheimer's. However, recognition of dementia is particularly difficult in its early stages. Clearly, many patients are not diagnosed and fail to receive treatment, particularly in the early disease stages when intervention may do the most good. |
|
||||||||
|
|||||||||
News
|
|||||||||
Get Involved:
Grass Roots Advocacy. Alzheimer's Association |
|||||||||